At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
The combination of radiation therapy and chemotherapy (chemoradiation) is a standard treatment for people with HPV-positive throat cancer. HPV is human papillomavirus and can cause throat cancer. Radiation therapy uses radiation to kill cancer cells and shrink tumors. Chemotherapy stops the growth of cancer cells, either by killing the cells or stopping them from dividing. However, this standard combination may cause severe side effects because it is given over 7 weeks. These side effects include sores in the mouth and gut, sore throat, and changes in taste.
-
Researchers are assessing a new treatment for people with prostate cancer that has not spread but has a high risk of spreading. The new treatment, 2141-V11, will be given with standard prostate cancer therapies.
-
Researchers want to learn how well zelenectide pevedotin works against advanced breast cancer. The people in this study have breast cancer that has come back, spread, or cannot be surgically removed. Their cancers are hormone receptor positive/HER2-negative or are triple negative. In addition, their tumor cells have an amplification (too many copies) of a gene called Nectin4.
-
Researchers want to find the best dose of REM-422 to use in people with advanced adenoid cystic cancer (ACC). ACC most commonly starts in the salivary glands. The people in this study have ACC that has spread and may high levels of a protein called MYB. This protein can cause cancer cells to grow.
- A Phase 1 Study of DAY301 in People With Advanced Solid Tumors
Full Title A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients with Locally Advanced or Metastatic Solid Tumors
Purpose
Researchers want to find the best dose of DAY301 to give to people with advanced solid tumors. The people in this study have solid tumors that have spread beyond their original location, including:
-
Head and neck cancer
-
Cancers of the esophagus, stomach, and gastroesophageal junction
- Non-small cell lung cancer and small cell lung cancer
- Gynecologic cancers: ovarian, endometrial, and cervical
-
Triple-negative breast cancer
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
DAY301 targets cells with a protein called PTK7, which plays a role in cancer growth. By destroying these cells, DAY301 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the advanced solid tumors listed above, which has spread beyond its original location.
- Have completed prior anti-cancer therapy at least 4 weeks before getting DAY301.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Robert Maki’s office at 646-888-5059.
Protocol
25-112Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06752681ClinicalTrials.gov
-
- A Phase 1 Study of ANS03 in People With Advanced Solid Tumors
Full Title A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants with Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Purpose
Researchers want to find the best dose of ANS03 to use and see how well it works in people with solid tumors that metastasized (spread). In addition, their tumors have mutations (changes) in the ROS1 or NTRK1/2/3 genes.
This study includes people with these cancers:
- Non-small cell lung cancer
- Gastric (stomach) cancer
- Breast cancer
- Esophageal cancer
- Pancreatic cancer
- Other types of solid tumors
ANS03 blocks proteins (ROS1 and TRK) that may be too active or found at high levels in your cancer cells. By blocking these proteins, ANS03 may help slow or stop the growth of your cancer. It is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have a metastatic solid tumor that cannot be cured with standard therapy.
- Have a tumor with an ROS1 or NTRK1/2/3 gene fusion.
- Have completed prior anti-cancer therapies at least 4 weeks before getting ANS03.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call 646-888-4226.
Protocol
25-099Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06716138ClinicalTrials.gov
-
Ruxolitinib is used to treat myelofibrosis, a rare bone marrow cancer that disrupts your body's normal blood cell production. Some people taking this drug, however, keep having symptoms. Researchers want to see if adding the drug ulixertinib to ruxolitinib treatment is safe and works better to treat myelofibrosis.